A single vaccination with protein-microspheres elicits a strong CD8 T-cell-mediated immune response against Mycobacterium tuberculosis antigen Mtb8.4

Vaccine

Volumn 22, Issue 15-16, 2004, Pages 1964-1972

  Evans, Jay T ^a   Ward, Jon R ^a   Kern, Jeff ^a   Johnson, Mark E ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Mycobacterium tuberculosis; PLG microspheres; Vaccine

Indexed keywords

ANTIGEN MTB8 4; BACTERIAL VACCINE; CD8 ANTIGEN; DOCUSATE SODIUM; GAMMA INTERFERON; GLUCOSE DERIVATIVE; IMMUNOLOGICAL ADJUVANT; MICROSPHERE; MPL; MYCOBACTERIUM ANTIGEN; PHOSPHORYL LIPID A; POLYGLACTIN; RC 529; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; DRUG FORMULATION; DRUG SCREENING; FEMALE; HUMORAL IMMUNITY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; T LYMPHOCYTE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, BACTERIAL; BACTERIAL PROTEINS; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CHROMIUM; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; INJECTIONS, INTRADERMAL; INJECTIONS, SUBCUTANEOUS; INTERFERON TYPE II; MICE; MICE, INBRED C57BL; MICROSPHERES; PARTICLE SIZE; SPLEEN; TUBERCULOSIS VACCINES; VACCINATION;

EID: 2342474615     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.10.035     Document Type: Article

References (47)

1. Tuberculosis. Fact sheet no. 104. World Health Organization; 2002.
2. Neuenschwander B.E., Zwahlen M., Kim S.J., Lee E.G., Rieder H.L. Determination of the prevalence of infection with Mycobacterium tuberculosis among persons vaccinated against bacillus Calmette-Guérin in South Korea. Am. J. Epidemiol. 155(7):2002;654-663
3. Colditz G.A., Brewer T.F., Berkey C.S., Wilson M.E., Burdick E., Fineberg H.V., et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. J. Am. Med. Assoc. 271(9):1994;698-702
4. Agger E.M., Andersen P. A novel TB vaccine towards a strategy based on our understanding of BCG failure. Vaccine. 21(1-2):2002;7-14
5. Coler R.N., Skeiky Y.A., Vedvick T., Bement T., Ovendale P., Campos-Neto A., et al. Molecular cloning and immunologic reactivity of a novel low molecular mass antigen of Mycobacterium tuberculosis. J. Immunol. 161(5):1998;2356-2364
6. Coler R.N., Campos-Neto A., Ovendale P., Day F.H., Fling S.P., Zhu L., et al. Vaccination with the T cell antigen Mtb8.4 protects against challenge with Mycobacterium tuberculosis. J. Immunol. 166(10):2001;6227-6235
7. Flynn J.L., Chan J. Immunology of tuberculosis. Annu. Rev. Immunol. 19:2001;93-129
8. Serbina N.V., Flynn J.L. CD8(+) T cells participate in the memory immune response to Mycobacterium tuberculosis. Infect. Immun. 69(7):2001;4320-4328
9. van Pinxteren L.A., Cassidy J.P., Smedegaard B.H., Agger E.M., Andersen P. Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells. Eur. J. Immunol. 30(12):2000;3689-3698
10. Silva C.L., Silva M.F., Pietro R.C., Lowrie D.B. Characterization of T cells that confer a high degree of protective immunity against tuberculosis in mice after vaccination with tumor cells expressing mycobacterial hsp65. Infect. Immun. 64(7):1996;2400-2407
11. Flynn J.L., Goldstein M.M., Triebold K.J., Koller B., Bloom B.R. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc. Natl. Acad. Sci. U.S.A. 89(24):1992;12013-12017
12. Scheerlinck J.Y. Genetic adjuvants for DNA vaccines. Vaccine. 19(17-19):2001;2647-2656
13. Taylor J.L., Turner O.C., Basaraba R.J., Belisle J.T., Huygen K., Orme I.M. Pulmonary necrosis resulting from DNA vaccination against tuberculosis. Infect. Immun. 71(4):2003;2192-2198
14. Reyes-Sandoval A., Ertl H.C. DNA vaccines. Curr. Mol. Med. 1(2):2001;217-243
15. Ulrich J.T., Myers K.R. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm. Biotechnol. 6:1995;495-524
16. Dhingra K., Papadopoulos N., Lippman S., Lotan R., Legha S.S. Phase II study of alpha-interferon and 13-cis-retinoic acid in metastatic melanoma. Invest. New Drugs. 11(1):1993;39-43
17. Evans J.T., Cluff C.W., Johnson D.A., Lacy M.J., Persing D.H., Baldridge J.R. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev. Vaccines. 2(2):2003;89-99
18. Tabata Y., Ikada Y. Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage. Biomaterials. 9(4):1988;356-362
19. Raychaudhuri S., Rock K.L. Fully mobilizing host defense: building better vaccines. Nat. Biotechnol. 16(11):1998;1025-1031
20. Falo L.D.J., Kovacsovics-Bankowski M., Thompson K., Rock K.L. Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nat. Med. 1(7):1995;649-653
21. Kovacsovics-Bankowski M., Rock K.L. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science. 267(5195):1995;243-246
22. Cohen S., Yoshioka T., Lucarelli M., Hwang L.H., Langer R. Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres. Pharm. Res. 8(6):1991;713-720
23. Shive M.S., Anderson J.M. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv. Drug Deliv. Rev. 28(1):1997;5-24
24. Vila A., Sanchez A., Tobio M., Calvo P., Alonso M.J. Design of biodegradable particles for protein delivery. J. Control. Release. 78(1-3):2002;15-24
25. Shahin R., Leef M., Eldridge J., Hudson M., Gilley R. Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(DL-lactide-co-glycolide) microspheres. Infect. Immun. 63(4):1995;1195-1200
26. Johansen P., Estevez F., Zurbriggen R., Merkle H.P., Gluck R., Corradin G., et al. Towards clinical testing of a single-administration tetanus vaccine based on PLA/PLGA microspheres. Vaccine. 19(9-10):2000;1047-1054
27. Hilbert A.K., Fritzsche U., Kissel T. Biodegradable microspheres containing influenza A vaccine: immune response in mice. Vaccine. 17(9-10):1999;1065-1073
28. Singh M., Li X.M., Wang H., McGee J.P., Zamb T., Koff W., et al. Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine. Infect. Immun. 65(5):1997;1716-1721
29. Moynihan J.S., Jones D.H., Farrar G.H., Howard C.R. A novel microencapsulated peptide vaccine against hepatitis B. Vaccine. 19(23-24):2001;3292-3300
30. Moore A., McGuirk P., Adams S., Jones W.C., McGee J.P., O'Hagan D.T., et al. Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells. Vaccine. 13(18):1995;1741-1749
31. Eldridge J.H., Staas J.K., Meulbroek J.A., McGhee J.R., Tice T.R., Gilley R.M. Biodegradable microspheres as a vaccine delivery system. Mol. Immunol. 28(3):1991;287-294
32. Hedley M.L., Curley J., Urban R. Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses. Nat. Med. 4(3):1998;365-368
33. Eldridge J.H., Staas J.K., Meulbroek J.A., Tice T.R., Gilley R.M. Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies. Infect. Immun. 59(9):1991;2978-2986
34. Maloy K.J., Donachie A.M., O'Hagan D.T., Mowat A.M. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles. Immunology. 81(4):1994;661-667
35. Partidos C.D., Vohra P., Anagnostopoulou C., Jones D.H., Farrar G.H., Steward M.W. Biodegradable microparticles as a delivery system for measles virus cytotoxic T cell epitopes. Mol. Immunol. 33(6):1996;485-491
36. Men Y., Tamber H., Audran R., Gander B., Corradin G. Induction of a cytotoxic T lymphocyte response by immunization with a malaria specific CTL peptide entrapped in biodegradable polymer microspheres. Vaccine. 15(12-13):1997;1405-1412
37. Men Y., Thomasin C., Merkle H.P., Gander B., Corradin G. A single administration of tetanus toxoid in biodegradable microspheres elicits T cell and antibody responses similar or superior to those obtained with aluminum hydroxide. Vaccine. 13(7):1995;683-689
38. Meyer J.D., Manning M.C. Hydrophobic ion pairing: altering the solubility properties of biomolecules. Pharm. Res. 15(2):1998;188-193
39. Ribi E.E., Strain S.M., Mizuno Y., Nowotny A., Von Eschen K.B., Cantrell J.L., et al. Peptides as requirement for immunotherapy of the guinea-pig line-10 tumor with endotoxins. Cancer Immunol. Immunother. 7:1979;43-58
40. Ismaili J., Rennesson J., Aksoy E., Vekemans J., Vincart B., Amraoui Z., et al. Monophosphoryl lipid A activates both human dendritic cells and T cells. J. Immunol. 168(2):2002;926-932
41. Baldridge J.R., Yorgensen Y., Ward J.R., Ulrich J.T. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. Vaccine. 18(22):2000;2416-2425
42. Baldridge JR. A synthetic adjuvant, RC-529, moves into the clinic. In: Proceedings of the Third Meeting on Novel Adjuvants Currently in/Close to Human Clinical Testing WHP/TDR, Foundation Merieux, 2002 [abstract].
43. Dupont J-C, Altclas J, Sigelchifer M, Von Eschen EB, Timmermans I, Wagener A. Efficacy and safety of AgB/RC529: a novel two dose adjuvant vaccine against hepatitis B. In: Proceedings of the 42nd ICAAC, San Diego, CA, 2002 [abstract].
44. Johnson D.A., Sowell C.G., Johnson C.L., Livesay M.T., Keegan D.S., Rhodes M.J., et al. Synthesis and biological evaluation of a new class of vaccine adjuvants: aminoalkyl glucosaminide 4-phosphates (AGPs). Bioog. Med. Chem. Lett. 9(15):1999;2273-2278
45. Kazzaz J., Neidleman J., Singh M., Ott G., O'Hagan D.T. Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1. J. Control. Release. 67(2-3):2000;347-356
46. Wilkinson K.A., Belisle J.T., Mincek M., Wilkinson R.J., Toossi Z. Enhancement of the human T cell response to culture filtrate fractions of Mycobacterium tuberculosis by microspheres. J. Immunol. Methods. 235(1-2):2000;1-9
47. Tracy M.A., Ward K.L., Firouzabadian L., Wang Y., Dong N., Qian R., et al. Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro. Biomaterials. 20(11):1999;1057-1062